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With the growing global antimicrobial resistance crisis, there is a critical need for alternatives
to conventional antibiotics, especially in developing countries. Virulent bacteriophages (phages)
represent a viable antibacterial technology that could be particularly beneficial, since phages are
active against antimicrobial-resistant bacteria, easy to isolate from contaminated environments,
and relatively inexpensive to produce. We discuss here examples of infectious diseases that
significantly affect developing countries, phage applications that could be especially impactful in
those settings, and special considerations for implementing phages in the developing world.
DEVELOPING COUNTRIES ARE DISPROPORTIONATELY
IMPACTED BY INFECTIOUS DISEASES
Bacterial infections cause more loss of life and health in developing nations than in wealthy
ones. As an example, infection with the bacteria Campylobacter is associated with an average case
fatality rate of ∼0.1% in developed countries, but in Kenya reportedly 8.8% of infected individuals
die, with most of those deaths occurring in children (O’Reilly et al., 2012; The Global View of
Campylobacteriosis, 2013). A 2014 report commissioned by the UK Prime Minister predicts that
by the year 2050, almost 10 million people will die from antibiotic-resistant infections annually:
roughly 4.73 million in Asia and 4.15 million in Africa, in contrast to 0.39 and 0.32 million in
Europe and the US, respectively (Antimicrobial Resistance: Tackling a Crisis for the Health and
Wealth of Nations, 2014). These numbers are actually underestimates, since they are based on
data available for only three of the seven bacteria that the World Health Organization has deemed
concerns.
Developing nations are also less able to prevent infections. Countries categorized as lower
middle income countries (LMIC)—defined as those with less than $4125 gross national income
per capita—are more likely to lack clean water and have sanitation and hygiene problems. Not
only are greater numbers of people affected by bacterial pathogens in LMIC, infected individuals
are often more vulnerable. Malnourished, immunocompromised, and HIV-positive patients have
more severe illnesses and greater risks. Given the public health and antibiotic resistance problems
in the developing world, alternative treatment modalities are urgently needed. Here, we describe
how phages are particularly appropriate for LMIC.
Abbreviations: LMIC, lower middle income countries.
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PHAGES ARE WELL-SUITED FOR
APPLICATIONS IN DEVELOPING
COUNTRIES
For over 100 years, virulent phages have been used in the
former Soviet Union as alternatives to and alongside traditional
antibiotics (Abedon et al., 2011). Therapeutic phages are
naturally occurring viruses that can be selected to kill only
specific bacterial species or strains while leaving other, helpful
bacteria and mammalian cells unharmed. Thus, unlike broad-
spectrum antibiotics, they spare the commensal microbiota
(e.g., in the gut)—a characteristic particularly important
for malnourished and immunocompromised individuals. In
addition, they can be effective against antibiotic-resistant
bacteria. Phages can be easily isolated from environments
enriched in targeted bacteria, such as hospital waste or sewage
water, with tools readily available to people in LMIC. In principle,
phage products can also be developed faster and more cost-
effectively than conventional drugs, and they can be dry powder
formulated so that they require no refrigeration (Semler et al.,
2012).
CURRENT AND POTENTIAL USES OF
PHAGES
Phage applications span a broad range, from food systems to
animal husbandry and clinical therapies. Generally, only lytic
phages are considered suitable for biocontrol or therapeutic
applications. Unlike temperate phages, lytic phages obligately
lyse bacteria and do not mediate the exchange of virulence or
antibiotic resistant determinants between bacteria.
Food Decontamination
Methodologies that address foodborne diseases are particularly
important for LMIC: many developing countries lack reliable
refrigeration and good hygiene practices, providing ample
opportunities for bacteria to grow. In Western countries, several
phage products are currently approved for the control of food
pathogens, including Listeria monocytogenes, Salmonella, and
Escherichia coli (Naanwaab et al., 2014). They are used as sprays
to decontaminate fruits, vegetables, cheese, fish, poultry, and
meats. If such phage products were available in developing
countries, their benefits could be even greater. For example, given
the scarcity of dependable refrigeration in many LMIC, meat
products are ideally sold within 24 h of slaughter. Thus, any
antibacterial product that could increase the shelf life by even 1
day could have significant impacts not only on public health, but
also on profitability for meat sellers.
Veterinary Applications
Phages could also be employed to decrease bacterial loads
in animals before they reach slaughterhouses. For instance,
Campylobacter is resident in the intestinal tracts of up to ∼75%
of poultry in many countries (Coker et al., 2002). While it
causes little harm to chickens, it is the leading bacterial cause
of gastroenteritis in humans worldwide. Data from Egypt shows
that in households with backyard poultry that are contaminated
with Campylobacter, children are almost four-fold more likely to
be infected with the bacteria (El-Tras et al., 2015). Numerous
studies have demonstrated that adding Campylobacter phages
to chicken feed can decrease bacterial levels in experimental
bird models by several orders of magnitude, presenting an
attractive biocontrol strategy (Connerton et al., 2011). However,
any applied phages would need to be active against the range of
bacterial strains present in poultry flocks, and the environmental
impacts of large-scale phage application should be studied in
greater depth (Marotta et al., 2015). If not managed properly,
bacteria could develop broader resistance to phages. Multiple
approaches can be employed to minimize such resistance,
including adapting the phages in vitro, utilizing phage cocktails,
and switching to different phages at regular intervals (Chan et al.,
2013). Phage preparations, especially for biocontrol applications,
will likely need to be tailor-made for specific settings and
will require periodic updates to address pathogen diversity as
well as evolutionary changes in bacterial populations (Hagens
and Loessner, 2010). Ideally, banks containing different, well-
characterized phages should be set up and regularly updated with
new phages.
Major economic markets in developing countries could also
benefit from phages. A prime example is the dairy industry, in
which bovine mastitis (inflammation of the mammary glands) is
the leading cattle disease worldwide (Dias et al., 2013). In India,
the largest producer of milk globally, bovine mastitis decreases
annual milk yields by up to 70%, with financial losses of over
$1 billion each year (Sharma et al., 2012; Padhy et al., 2015).
Since bovinemastitis is mainly caused by bacteria (Staphylococcus
and Streptococcus) where antimicrobial resistance is increasing,
alternatives to antibiotic treatment are urgently needed. Bovine
infections also affect human health: low levels of contamination
can be difficult to detect, often leaving bacteria to be
propagated and transferred to humans through milk products
(Hameed et al., 2006; Wareth et al., 2014). By decreasing such
infections in dairy cattle, phages could potentially contribute
to both the financial and medical health of populations
in LMIC.
Human Treatment
Over the past century, phages have been administered in some
regions directly to people, either as prophylaxis or to treat active
infections (Abedon et al., 2011). In the 1960s, phages were
tested for the prevention of seasonal Shigella infections in the
country of Georgia. More than 30,000 children received Shigella
phages or a placebo, and there was a statistically significant
reduction in the Shigella infection rate in the phage-treated group
(Kutter et al., 2010). Estimates indicate that Shigella species
infect 164.7 million people annually—with 163.2 million of those
cases occurring in developing countries, resulting in 1.1 million
deaths each year (Kotloff et al., 1999). Since Shigella strains
now exhibit worrying rates of resistance to antibiotics, even to
third generation cephalosporins, there is significant motivation
to explore using Shigella phages in LMIC.
In the 1920s and 1930s, several studies were conducted in
India testing the efficacy of orally delivered cholera phages
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(Summers, 1993). In one study series involving more than 800
patients, there were consistently fewer deaths in the patients
who received phages. Another study tested the ability of phages
to control cholera outbreaks in hundreds of villages. Two
comparable (in terms of yearly cholera outbreak patterns) yet
geographically separate village regions were monitored, with one
of the regions receiving phage treatment and the other not. In
the treated region there were no epidemics during the 6-year
course of the study, whereas in the untreated region there were
seasonal epidemics in the first 3 years. After that, the government
ordered phage treatment in both regions, with almost no cholera
cases reported during the following 3 years. The discovery and
early promise of antibiotics in the 1940s eventually led to the
abandonment of phage therapies such as these. Now, given the
problems of antimicrobial resistance, it is appropriate to give
phages another look.
While historical phage studies were not always conducted
according to the rigors of modern clinical trials, they do
strongly suggest that phages could be useful in outbreak settings,
such as in the Haiti cholera epidemic of 2010, which affected
more than 700,000 people. In such situations, phages could
help fill gaps that are not fully addressed by current vaccine
and hygiene strategies. For example, phage treatment could be
particularly helpful for non-vaccinated populations, since phages
could work in parallel with vaccines, beginning to kill intestinal
bacteria within hours, while vaccines take weeks to provide
full immunological protection. Phages should also be beneficial
to immunocompromised individuals, whose immune systems
often are not fully responsive to vaccines. And while vaccines
require refrigeration, lyophilized phages can be stored at room
temperatures (Semler et al., 2012). Thus, phages could be an
effective addition to the arsenal of tools already available to
combat cholera outbreaks.
REGULATORY CONSIDERATIONS
To fully realize the public health benefits of phages in LMIC, each
country will need to establish appropriate regulatory guidelines.
Unfortunately, traditional regulatory systems are not well-suited
for the development of sustainable phage products. For example,
most regulatory structures focus on drugs that are composed
of a single chemical entity, whereas phage preparations would
ideally be custom-made and updated at regular intervals to
both enhance their efficacy and minimize the development of
bacterial resistance. Since phages are naturally occurring entities,
many experts have argued that a different type of regulatory
process should be established for phages, perhaps something
closer to that governing probiotics. One alternative approach
currently being explored at the Queen Astrid Military Hospital
in Belgium is to produce phages in compliance with a formal
monograph describing the standards by which the phage quality
will be judged for specific applications (e.g., pharmaceuticals,
dietary supplements, or food ingredients; Merabishvili et al.,
2009).
IMPORTANCE OF LOCAL CULTURAL
CONTEXTS
Even though phages have a long history of being used as
antibacterial agents in some regions of the world, they are
a relatively new technology in most countries, especially in
this modern era. As such, phages are bound to elicit fear
and myths as novel biocontrol substances. To clarify any
misperceptions, all potential stakeholders must engage in
public dialogue—from regulatory authorities and policymakers
to farmers, merchants, health care practitioners, and people
who might receive treatment. Workshops with relevant
stakeholders could provide information regarding the potential
benefits of phages, address concerns, and gain input on
how phages could be utilized suitably within a local social
setting. The criteria and processes by which phages would
be certified as safe should be clearly communicated, and
the ways they will be regulated and monitored must be
explicitly defined. Facilitation of public discussion about phages
can broaden acceptance of this new class of antibacterial
products.
While there is great potential for phage applications,
considerable work must be done before phages can be
adopted in LMIC. It will be important to better understand
how phages co-evolve with their bacterial hosts, to develop
processes for regularly updating phage cocktails, and to
optimize phage therapy regimens. In addition, safety assessments,
regulatory procedures, and cultural buy-in will all be essential.
Obtaining intellectual property can be difficult, especially
on naturally occurring phages, so there is also a need to
create commercial incentives other than patents to encourage
companies to develop new phage products. Perhaps progress
in this area will be motivated by both the immense public
health needs, as well as by the tremendous size of developing
country emerging markets. Ultimately, phage products have the
potential to transform how infectious diseases are addressed
in developing countries, helping to save lives as well as build
economies.
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